secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001628280-23-041271
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics enters license and collaboration agreement with Merck to develop degrader-antibody conjugates
--------------------------------------------------------------------------------

- C4T grants Merck worldwide exclusive license for DACs directed to an initial undisclosed oncology target.
- Merck pays $10 million upfront; C4T eligible for up to ~$600 million in milestones for initial target plus tiered royalties.
- Merck has options for three additional targets; if all exercised, total potential payments to C4T up to ~$2.5 billion.
- Collaboration leverages C4T's TORPEDO platform for degrader payloads and Merck's antibody conjugation expertise.
- Merck responsible for all development, regulatory, manufacturing, and commercialization costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023041271/0001628280-23-041271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023041271/cccc-20231212.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-041271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer